PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Declining payables indicates faster supplier payments but reduces free financing. Howard Marks would verify liquidity remains adequate.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-502.30%
Declining other current liabilities reduces near-term obligations. Benjamin Graham would see this as improving short-term financial position.
-57.89%
Declining current liabilities reduces short-term financial pressure. Seth Klarman would see this as improving liquidity position.
43.72%
Above 5% yoy – expanding LT debt. Philip Fisher demands clarity on whether growth justifies added leverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.72%
Above 5% yoy – rising long-term liabilities. Philip Fisher wants clarity on new debts or deferrals.
No Data
No Data available this quarter, please select a different quarter.
20.19%
Above 10% yoy – large jump. Philip Fisher demands clarity on whether growth justifies the leverage.
No Data
No Data available this quarter, please select a different quarter.
-1.97%
Declining retained earnings signals net losses or large dividends. Seth Klarman would investigate the sustainability of dividend policy.
No Data
No Data available this quarter, please select a different quarter.
-86.83%
Declining other equity items simplifies the capital structure. Benjamin Graham would favor this reduction in complexity.
-20.70%
Declining stockholders equity may signal losses or large distributions. Seth Klarman would investigate the underlying causes and sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.72%
Above 5% yoy – debt expansion. Philip Fisher demands clarity on whether new debt is productive or just adding leverage.
45.18%
Above 5% yoy – net debt expansion. Philip Fisher demands clarity on the reason for higher leverage vs. cash.